Recent evidence regarding resection rate, specialism and survival in lung cancer in the UK

Similar documents
National analysis of lung cancer data: overview

Impact of cancer symptom awareness campaigns on diagnostic testing and treatment

The effect of surgeon volume on procedure selection in non-small cell lung cancer surgeries. Dr. Christian Finley MD MPH FRCSC McMaster University

National Lung Cancer Audit outlier policy for Wales 2017

Staging Issues: Lung Cancer & Mesothelioma. Mick Peake Clinical Lead, NCIN Chair, Lung SSCRG

National Lung Cancer Audit outlier policy 2017

Recent advances in the management of Lung Cancer

National Lung Cancer Audit Lung cancer consultant outcomes publication 2016 (for the 2013 audit period)

Module 2. Dr Anna Gavin Mr Conan Donnelly Dr Michael Donnelly Dr David Donnelly

NICaN workshop: Colorectal Cancer Follow-up

Developing Key Messages on Cancer for Commissioners

National Bowel Cancer Audit Supplementary Report 2011

WHERE NEXT FOR CANCER SERVICES IN WALES? AN EVALUATION OF PRIORITIES TO IMPROVE PATIENT CARE

NATIONAL BOWEL CANCER AUDIT The validity of cancer-specific mortality as a performance indicator in patients having major surgery for bowel cancer

Cancer Research UK response to All Party Parliamentary Group on Cancer consultation Cancer across the Domains

SCHEDULE 2 THE SERVICES

Developing Key Messages on Cancer for Commissioners

NATIONAL BOWEL CANCER AUDIT The feasibility of reporting Patient Reported Outcome Measures as part of a national colorectal cancer audit

Dr Megan Rowley. CONSULTANT HAEMATOLOGIST - NHSBT and Imperial

THE INTERNATIONAL CANCER BENCHMARKING PARTNERSHIP: GLOBAL LEARNING FROM OUR RESULTS Harpal Kumar, Chief Executive, Cancer Research UK UICC World

Lung cancer clinical outcomes publication 2016 (for the 2014 audit period)

Challenges for the Lung Cancer Pathway Group

WHERE NEXT FOR CANCER SERVICES IN NORTHERN IRELAND? AN EVALUATION OF PRIORITIES TO IMPROVE PATIENT CARE

Management and survival of patients with lung cancer in Scotland diagnosed in 1995: results of a national population based study

National Breast Cancer Audit next steps. Martin Lee

Co-morbidity: a summary of issues from the NCIN Site-Specific Clinical Reference Groups Dr Mick Peake

Downloaded from:

Surgery for early stage NSCLC

Lung cancer: the importance of seeing a respiratory physician

Understanding surgery

Audit Report Report of the 2011 Clinical Audit Data

Outcome following surgery for colorectal cancer

Collaborators. ICBP Module 5 Working Group

Audit Report. Report of the 2010 Clinical Audit Data. West of Scotland Cancer Network. Lung Cancer Managed Clinical Network

NCIN Conference Feedback 2015

LUNG CANCER 2010 COMPARATIVE AUDIT REPORT

International Cancer Benchmarking Partnership Wales Newsletter

National Diabetes Audit

7/11/2011. The impact of cancer survival studies on health policy. NCI prevention budget falls. Cases Deaths Survivors

Lung Cancer 2013 Peer Review All Wales Report

ONLINE SUPPLEMENTARY MATERIAL

A Global perspective on Heart Failure: What needs to change? Martin R Cowie London, United Kingdom

National Optimal Lung Cancer Pathways. Dr Sadia Anwar Nottingham University Hospitals NHS Trust Clinical Lead for Lung Cancer

Apples and pears? A comparison of two sources of national lung cancer audit data in England

Health Board/Region: All-Wales

Cancer and Data in the New NHS May Di Riley, Director Clinical Outcomes

Lung cancer care in Victoria

Report prepared on behalf of the Scottish Head and Neck Cancer Networks by the WoSCAN Information Team

National Prostate Cancer Audit. Bill Cross June 2015

The surgeon: new surgical aproaches

Variation in optimal pre-diagnostic pathway in lung cancer patients in 2013 & 2014 using cancer registrations and the diagnostic imaging dataset

Cost-effective commissioning of colorectal cancer care: An assessment of the cost-effectiveness of improving early diagnosis

SELF ASSESSMENT REPORT (MULTI-DISCIPLINARY TEAM)

National Mesothelioma Audit. National Mesothelioma Audit report 2018 (for the audit period )

A06/S(HSS)b Ex-vivo partial nephrectomy service (Adult)

On-going and planned colorectal cancer clinical outcome analyses

NLCA annual report analysis 2017 (for the population of 2016)

Reference No: Author(s) NICaN Drugs and Therapeutics Committee. Approval date: 12/05/16. January Operational Date: Review:

surgical approach for resectable NSCLC

The right middle lobe is the smallest lobe in the lung, and

National Lung Cancer Audit annual report 2016 (for the audit period 2015)

Cancer in Elderly in Denmark

Deceased donation data in the UK. Paul Murphy National Clinical Lead for Organ Donation United Kingdom

Quality metrics for resection: Are they reasonable?

Lung Cancer Diagnostic Pathway Analysis

Care of lung cancer patients in Northern Ireland diagnosed 2014

The 7th Edition of TNM in Lung Cancer.

Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study,

INFORMATION TO SUPPORT THE DEVELOPMENT OF THE LINCOLNSHIRE CANCER STRATEGY

Cancer and Data in the New NHS May Di Riley, Director Clinical Outcomes

Thoracic and head/neck oncology new developments

Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study,

Lung cancer is the leading cause

Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy

Prevention of Bowel Cancer: which patients do I send for colonoscopy?

Clinical Commissioning Policy: Vagal Nerve Stimulation (VNS) December Reference : NHSCB/D4/c/7

Informatics in the new NHS : PHE and NCIN 9 months on. Nicky Coombes National Cancer Intelligence Network

Dual Diagnosis. Themed Review Report 2006/07 SHA Regional Reports East Midlands

SAFE HIP FRACTURES. Dr Karthik Kayan MD FRCP Consultant Physician and Orthogeriatrician Stockport NHS Foundation Trust

T3 NSCLC: Chest Wall, Diaphragm, Mediastinum

for healthcare professionals

STS General Thoracic Surgery Database (GTSD) Update

Understanding lymphoma: the importance of patient data

Implementing the NICE Guidelines

HIV in London: A Complexity Challenge

Chapter 6: Adequacy of haemodialysis (Urea reduction ratio)

Ruth Howkins Deputy National Coordinator National Cancer Peer Review

Audit Report. Lung Cancer Quality Performance Indicators. Patients diagnosed April 2014 March Published: May 2016

NICE Quality Standards and COF

Shared Care Pathway for Soft Tissue Sarcomas Presenting to Site Specialised MDTs Lung /chest wall sarcomas incl. pulmonary metastatectomy Version 2

Inequity in access to guideline-recommended colorectal cancer treatment in Nova Scotia, Canada

Resource impact report: Eating disorders: recognition and treatment (NG69)

PARTICULARS, SCHEDULE 2- THE SERVICES, A- SERVICE SPECIFICATIONS. A17/S(HSS)/a Congenital hyperinsulinism service (Children)

Proper Treatment Selection May Improve Survival in Patients With Clinical Early-Stage Nonsmall Cell Lung Cancer

Promoting Innovative Practice

Cancer Outcomes and Services Dataset: Implications for clinical teams

Diagnosing Cancer Earlier: reviewing the evidence for improving cancer survival 3 rd NAEDI Research Conference

Lung Cancer Patient Outcomes

GETTING IT RIGHT FIRST TIME National Professional Pilot

An Overview of Health Economics Data and Expertise in Cancer

Transcription:

Recent evidence regarding resection rate, specialism and survival in lung cancer in the UK Dr Mick Peake Glenfield Hospital, Leicester Clinical Lead, National Cancer Intelligence Network & National Lung Cancer Audit National Clinical Lead, NHS Cancer Improvement

New data Link between resection rate & survival (Riaz S et al. Eur J Cancer 2012;48:54-60) Rising, but variable resection rate (National Lung Cancer Audit, SCTS audit, Riaz et al., in press) Evidence of a strong link between specialisation (and MDT attendance by surgeons) and resection rate (Rich et al, Thorax 2011;66:1078-1084; Lau et al, WCLC Amsterdam & paper in preparation) Increase in resection rate after introduction of thoracic surgeon (Martin-Ucar et al. Lung Cancer. 2004; 46:227-232) Improved quality of surgical practice (SCTS audit) Increase in total number of thoracic surgeons Emerging evidence of stage-for-stage lower survival rates in UK (International cancer Benchmarking Partnership)

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 % of patients undergoing surgical resection Proportion of lung cases having a pneumonectomy (%) Resection rate by PCT 2004-6* 18 16 14 12 10 8 Q1 Q2 Q3 Q4 Q5 6 4 2 0 PCT of residence Source: Riaz S et al. Eur J Cancer 2012;48:54-60

Mortality Hazard Ratios for Lung Cancer Patients in England 2004-6 related to resection rate by government office region 1.05 SE N = 77,349 1.00 EE SW NE NW Y&H EM 0.95 WM 0.90 L 0.85 5 6 7 8 9 10 11 Radical surgery (%) Hazard ratio 95% CI Radical surgery 95% CI Source: Riaz S et al. Eur J Cancer 2012;48:54-60

N39 N03 N35 N11 N20 N22 N32 N08 Nir N06 N31 N36 N33 N28 N26 N02 SCAN NWW N37 N01 N07 WSCAN N21 N30 N12 SWCN N29 N34 N23 N38 N25 N24 N27 NSCAN % 25.0 20.0 Surgery in confirmed NSCLC (%) England Scotland Wales N Ireland 15.0 10.0 5.0 0.0

N20 N22 N32 N35 N39 N03 N33 N31 N23 N12 N08 N37 N06 N36 N34 N11 N26 N30 N28 N07 N02 N29 N27 NWW N21 N38 N24 N25 N01 SWCN Odds Ratio 2.50 Surgery in confirmed NSCLC (%, England & Wales only) 2.00 1.50 1.00 0.50 0.00

N07 N35 N30 N28 N39 N31 N29 N38 N08 N32 N11 N22 Nir N03 N12 N37 N23 N20 N21 N25 N26 N33 N36 N01 NWW N02 N24 N06 N34 N27 SWCN % 70.0 60.0 Surgery in Stage I/II NSCLC (%) England Wales N Ireland 50.0 40.0 30.0 20.0 10.0 0.0

Case ascertainment (%) National Lung Cancer Audit (England) Headline indicators over time 2005 2006 2007 2008 2009 2010 40 66 75 92 >97 ~100 % discussed at MDT 79 84.3 86.8 88.6 93.8 96.1 Tissue confirmation rate (%) Overall surgical resection rate (%) Resection rate: confirmed NSCLC (%) Active treatment rate (%) Small Cell chemotherapy rate (%) 68 66 65 66.7 75.9 76.5 9 9.4 10.3 11.2 13.9 13.9 13.8 14.3 15.2 16.0 18.4 18.3 45 50 52 54 59.2 58 57.7 61.7 64.5 63.0 65.4 65

Resection Rate % 20 18 16 14 12 10 8 6 4 2 0 Resection rate (England & Wales): National Lung Cancer Audit Confirmed NSCLC All patients 2005 2006 2007 2008 2009 2010

Resection rate: trend by year Source: Riaz et al, Thorax; in press

Resection rate: trend by age Source: Riaz et al, Thorax; in press

% Change in consultant numbers between 2000 and 2010 140 120 100 80 60 40 20 0

Resection rate for patients with tissue confirmation of NSCLC (2004-2008:England) First seen in centre with thoracic surgery? Number With a tissue diagnosis of NSCLC Number who had surgical resection % having surgery Adjusted Odds Ratio for surgery* No 25,248 2,947 12% 1.00 Yes 9,265 (27%) 1,538 17% 1.51 (1.16-1.97) P value <0.001 *adjusted for sex, age, PS, stage, deprivation index and Charlson co-morbidity index Rich et al; Thorax 2011;66:1078-1084

Resection Rate Resection rates are higher in base than in referring centres Across the UK Within each Cancer Network 25% 20% 20% p < 0.001 15% p < 0.001 15% 10% 10% 5% 5% 0% Base Peripheral 0% Base Peripheral Source: Lau et al; J Thor Onc, 2011:(abstract)

Resection Rate Resection rates are higher in centres with 2 or more specialist thoracic surgeons 25% p = 0.02 20% 15% 10% 5% 0% Less than 2 2 or More Source: Lau et al; J Thor Onc, 2011:(abstract)

Resection rates are higher when surgeons attend preoperative MDTs 16 p = 0.012 14 12 10 8 6 4 2 0 Less than two-thirds More than two-thirds Source: Lau et al; J Thor Onc, 2011:(abstract)

Resection Rate The increase in resection rate was greatest in those units who employed new thoracic surgeons 20 p = 0.04 15 10 19% 66% 2009 Growth 5 2008 0 Static Expanded (5 Units) Source: Lau et al; J Thor Onc, 2011:(abstract)

Surgical Resection Rate - Leicester Surgical Numbers Resection Rate for confirmed NSCLC 1994-1996* 65 12.2 4.5 1997-1999* 175 23.4 12.0 2002 45 19.9 12.7 2003 58 21.0 13.8 2004 60 20.8 13.5 2005 89 30.4 20.6 2006 94 31.1 19.3 2007 23.5 17.4 2008 33.3 22.2 2009 22.7 15.8 2010 23.7 16.3 Resection Rate for all Lung Cancers * A Martin-Ucar et al. Lung Cancer. 2004; 46:227-232

Leicester: Median survival by year of diagnosis MS (months) P <0.001 7 6 5 4 3 2 1 0 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008

1yr survival in lung cancer patients diagnosed 2000-2007 by stage 100 90 80 70 60 50 40 30 20 10 0 Canada Sweden Denmark UK All stages TNM1 TNM2 TNM3 TM4 Missing Source: International Cancer Benchmarking Partnership: Walters, Maringe, Rachet, Coleman et al (in preparation)

1yr survival in lung cancer patients diagnosed 2000-2007 by stage 100 90 80 70 60 50 40 30 20 10 0 Over 35% of UK patients unstaged (<10% in others except Australia - ~20%) Canada Sweden Denmark UK All stages TNM1 TNM2 TNM3 TM4 Missing Source: International Cancer Benchmarking Partnership: Walters, Maringe, Rachet, Coleman et al (in preparation)

Source: R Page, Society of Cardiothoracic Surgeons Audit 2011

Source: R Page, Society of Cardiothoracic Surgeons Audit 2011

Source: R Page, Society of Cardiothoracic Surgeons Audit 2011

Source: R Page, Society of Cardiothoracic Surgeons Audit 2011

Source: R Page, Society of Cardiothoracic Surgeons Audit 2011

Source: R Page, Society of Cardiothoracic Surgeons Audit 2011

New data Link between resection rate & survival (Riaz S et al. Eur J Cancer 2012;48:54-60) Rising, but variable resection rate (National Lung Cancer Audit, SCTS audit, Riaz et al., in press) Evidence of a strong link between specialisation (and MDT attendance by surgeons) and resection rate (Rich et al, Thorax 2011;66:1078-1084; Lau et al, WCLC Amsterdam & paper in preparation) Increase in resection rate after introduction of thoracic surgeon (Martin-Ucar et al. Lung Cancer. 2004; 46:227-232) Improved quality of surgical practice (SCTS audit) Increase in total number of thoracic surgeons Emerging evidence of stage-for-stage lower survival rates in UK (International cancer Benchmarking Partnership)

Conclusions Rapid recent increase in availability of data on surgical practice and outcomes More work needed on relationship of treatment rates and survival (not only surgery) There remains a need for more specialist thoracic surgeons Increasing resection rates in older patients prompt questions about patient-reported outcome measures We need to use these data in discussions with local service providers and commissioners